Trulieve Could Benefit From Uplisting To Major Index

Trulieve is considering an uplisting of its stock, while also expecting to benefit from the rescheduling of medical cannabis. The company’s recently reported Q1-2026 results were in line with expectations, indicating stable near-term fundamentals. The combination of a potential listing upgrade and a favorable regulatory backdrop is modestly positive for the shares.

Analysis

Trulieve is considering an uplisting of its stock, while also expecting to benefit from the rescheduling of medical cannabis. The company’s recently reported Q1-2026 results were in line with expectations, indicating stable near-term fundamentals. The combination of a potential listing upgrade and a favorable regulatory backdrop is modestly positive for the shares.